Floatz logo

azd3839

Safety

AstraZenecaPhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

31 Active assets in the Safety cohort.

Asset / SponsorPhaseRating
Bortezomib
Shandong Provincial Hospital
Phase 4BB
Gemtuzumab Ozogamicin
Pfizer
Phase 4BB
Namenda
First Affiliated Hospital Xi'an Jiaotong University
Phase 4B
Famitinib
Anhui Provincial Hospital
Phase 3B
Inno-206
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4B

View all 48 →

Same molecule, other indications

azd3839 is also rated in:

TolerabilityDormant
CC
Indicative ·
46 / 100
View asset →
Healthy VolunteersDormant
CC
Indicative ·
44 / 100
View asset →
Alzheimer diseaseDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →